Double-label time-resolved immunofluorometric assay of prostate-specific antigen and of its complex with alpha 1-antichymotrypsin.
We have developed a procedure for simultaneous immunofluorometric assay (IFMA) of prostate-specific antigen (PSA) and its complex with alpha 1-antichymotrypsin (ACT). A PSA-specific monoclonal antibody, which captures both free PSA and the PSA-ACT complex, was used as solid-phase antibody. Total PSA immunoreactivity was measured with a Eu(3+)-labeled PSA antibody that reacted with both free PSA and PSA-ACT. PSA-ACT was assayed simultaneously with a Sm(3+)-labeled polyclonal ACT antibody as a tracer. As standard we used pooled serum in which most of the PSA occurred as the PSA-ACT complex. The assay range was 0.03-500 micrograms/L for total PSA and 0.16-450 micrograms/L for PSA-ACT. In comparison with the assay for total PSA, assay of the PSA-ACT/PSA ratio improved the clinical specificity for cancer by reducing the number of false-positive results in prostatic hyperplasia.
Leinonen
J
J
Department I of Obstetrics and Gynecology, Helsinki University Central Hospital, Finland.
Lövgren
T
T
Vornanen
T
T
Stenman
U H
UH
D002850:Chromatography, Gel; D005260:Female; D015200:Fluoroimmunoassay / Q000379:methods* / Q000706:statistics & numerical data; D005615:Freezing; D006801:Humans; D008297:Male; D017430:Prostate-Specific Antigen / Q000097:blood*; D011470:Prostatic Hyperplasia / Q000276:immunology; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000276:immunology; D011786:Quality Control; D012680:Sensitivity and Specificity; D000514:alpha 1-Antichymotrypsin / Q000378:metabolism*
D000514:alpha 1-Antichymotrypsin; D017430:Prostate-Specific Antigen